275 related articles for article (PubMed ID: 11140743)
1. The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.
Kwok JC; Richardson DR
Redox Rep; 2000; 5(6):317-24. PubMed ID: 11140743
[TBL] [Abstract][Full Text] [Related]
2. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
Kik K; Szmigiero L
Postepy Hig Med Dosw (Online); 2006; 60():584-90. PubMed ID: 17115008
[TBL] [Abstract][Full Text] [Related]
3. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
Herman EH; Ferrans VJ
Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
Stěrba M; Popelová O; Vávrová A; Jirkovský E; Kovaříková P; Geršl V; Simůnek T
Antioxid Redox Signal; 2013 Mar; 18(8):899-929. PubMed ID: 22794198
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of dexrazoxane.
Hochster HS
Semin Oncol; 1998 Aug; 25(4 Suppl 10):37-42. PubMed ID: 9768822
[TBL] [Abstract][Full Text] [Related]
6. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
7. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
8. Strategies for reduction of anthracycline cardiac toxicity.
Speyer J; Wasserheit C
Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
[TBL] [Abstract][Full Text] [Related]
9. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of cytotoxic drugs.
Schimmel KJ; Richel DJ; van den Brink RB; Guchelaar HJ
Cancer Treat Rev; 2004 Apr; 30(2):181-91. PubMed ID: 15023436
[TBL] [Abstract][Full Text] [Related]
11. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
Hasinoff BB; Hellmann K; Herman EH; Ferrans VJ
Curr Med Chem; 1998 Feb; 5(1):1-28. PubMed ID: 9481032
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline cardiotoxicity in children.
Kremer LC; Caron HN
N Engl J Med; 2004 Jul; 351(2):120-1. PubMed ID: 15247351
[No Abstract] [Full Text] [Related]
13. Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients.
Kang M; Kim KI; Song YC; Shin WG; Oh JM
J Chemother; 2012 Oct; 24(5):292-6. PubMed ID: 23182049
[TBL] [Abstract][Full Text] [Related]
14. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
Cvetković RS; Scott LJ
Drugs; 2005; 65(7):1005-24. PubMed ID: 15892593
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Anderson B
Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
[TBL] [Abstract][Full Text] [Related]
16. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
Hasinoff BB
Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
[TBL] [Abstract][Full Text] [Related]
17. Dexrazoxane (ICRF-187).
Weiss G; Loyevsky M; Gordeuk VR
Gen Pharmacol; 1999 Jan; 32(1):155-8. PubMed ID: 9888268
[TBL] [Abstract][Full Text] [Related]
18. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
19. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
Wexler LH
Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
[TBL] [Abstract][Full Text] [Related]
20. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
